Literature DB >> 27268750

Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.

Yuan Tang1, Yue Wang2, Mohammad F Kiani1, Bin Wang3.   

Abstract

Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our understanding of breast cancer has improved greatly in recent years. In this review, we examine different types of breast cancer and summarize their clinical features, current treatment schemes, and potential drug resistance profiles in response to treatments. We believe that the understanding of the molecular mechanisms of each treatment and subsequent drug resistance development will eventually lead to the discovery of more effective and efficient second-line therapeutics.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical trials; Endocrine therapy; Pathways; Treatment strategies; Triple-negative breast cancer

Mesh:

Substances:

Year:  2016        PMID: 27268750     DOI: 10.1016/j.clbc.2016.05.012

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  68 in total

1.  Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance.

Authors:  Sheng-Yen Lin; Sung-Yuan Hsieh; Yi-Ting Fan; Wen-Chi Wei; Pei-Wen Hsiao; Dai-Hua Tsai; Tzong-Shoon Wu; Ning-Sun Yang
Journal:  Autophagy       Date:  2017-12-31       Impact factor: 16.016

2.  CoAsy knockdown in TNBC cell lines resulted in no overt effect on cell proliferation in vitro.

Authors:  Hamzah A Kharabsheh; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2020-07-31       Impact factor: 3.575

Review 3.  Emerging roles of aerobic glycolysis in breast cancer.

Authors:  Z Wu; J Wu; Q Zhao; S Fu; J Jin
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

Review 4.  PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Authors:  Jill J J Geenen; Sabine C Linn; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

5.  Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3.

Authors:  Jianliang Shen; Linwen Zeng; Liangming Pan; Shaofeng Yuan; Ming Wu; Xiongdong Kong
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

6.  P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.

Authors:  Chengqiong Mao; Yan Zhao; Fang Li; Zibo Li; Shaomin Tian; Waldemar Debinski; Xin Ming
Journal:  J Control Release       Date:  2018-08-04       Impact factor: 9.776

7.  The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression.

Authors:  Xiaohong Xia; Chuyi Huang; Yuning Liao; Yuan Liu; Jinchan He; Zhenlong Shao; Tumei Hu; Cuifu Yu; Lili Jiang; Jinbao Liu; Hongbiao Huang
Journal:  Cell Death Dis       Date:  2021-03-26       Impact factor: 8.469

8.  Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

Authors:  Huseyin Beyaz; Hasan Uludag; Doga Kavaz; Nahit Rizaner
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.

Authors:  Samia S Messeha; Najla O Zarmouh; Karam F A Soliman
Journal:  Nutrients       Date:  2021-05-19       Impact factor: 5.717

Review 10.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.